What initially seems like purely psychological trouble may indeed have roots in physical conditions that, once identified, ...

The "Carcinoid Tumor Market" report has been added to ResearchAndMarkets.com's offering. The global demand for advanced carcinoid tumor treatments is witnessing a profound acceleration, as evidenced ...

Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for ...

Nikki Gooding, a Virginia-based family aesthetics nurse practitioner, shared that concerning data generated from her Oura ring encouraged her to seek medical treatment.

PhD Defense: From the Outside In; Exploring the Role of the Exposome and Circadian Clock in Cardiovascular Disease – From Mechanisms to Therapeutics ...

Some cancers, such as carcinoid cancer, grow extremely slowly. Years or even decades may pass before they cause noticeable symptoms. During this time, the cancer may go undetected. Cancer may also ...

The NHS is urging thousands of people to cut down on their intake of tea and coffee due to an uncomfortable side effect ...

Mutiibwa, D. , Turanzomwe, S. , Atukunda, E. and Mugyenyi, G. (2025) Colonoscopy Findings at Divine Mercy Hospital-Father ...

Enrollment of the first patient in the pivotal Phase 3 trial of paltusotine in carcinoid syndrome is anticipated in the second quarter of 2025. Crinetics expects to begin enrollment of patients in two ...

The aim of this surgery is to control the cancer and to help with symptoms. Doctors call this palliative surgery. Surgery is the main treatment for typical carcinoid (TC) and atypical carcinoid (AC).

Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

Aim/introduction: Peptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs progression-free ...